Pachon J, Lorber M I, Bia M J
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
Transplantation. 1989 Feb;47(2):254-9. doi: 10.1097/00007890-198902000-00011.
H2-receptor antagonists have been frequently avoided in cyclosporine-treated transplant patients because of concern regarding possible exacerbation of nephrotoxicity. To determine whether the reported increase of serum creatinine levels in cyclosporine-treated transplant patients receiving H2-receptor antagonists was due to a true decrease in glomerular filtration rate or was secondary to altered renal tubular handling of creatinine, simultaneous inulin and creatinine clearances were analyzed in 11 cyclosporine-treated renal transplant recipients before and after H2-receptor antagonist administration. Seven patients received one week of cimetidine 300 mg p.o. four times daily and eight received one week of ranitidine 150 mg p.o. two times daily. Prior to study, all patients had stable renal function and were maintained on prednisone (mean dose 0.2 +/- 0.01 mg/kg/day) and cyclosporine (mean dose 5 +/- 0.6 mg/kg/day). Four patients were also receiving azathioprine (2 mg/kg/day). Cimetidine administration resulted in a significant increase (P less than 0.05) in mean serum creatinine concentration from 2.0 +/- 0.3 mg/dl to 2.4 +/- 0.3 mg/dl and a significant reduction (P less than 0.05) in mean creatinine clearance remained unchanged during this same period. Serum creatinine levels returned to baseline values for all patients following discontinuation of the drug. Ranitidine administration had no consistent effect on serum creatinine concentration, creatinine clearance or inulin clearance. Cyclosporine trough levels and BUN were unchanged by either drug. These results confirm previous observations demonstrating an increase in serum creatinine and a reduction in creatinine clearance following administration of H2 receptor antagonists, especially cimetidine. Failure to document a simultaneous reduction in inulin clearance is consistent with the hypothesis that H2-receptor antagonists do not exacerbate cyclosporine nephrotoxicity and lower GFR, but rather compete with creatinine for tubular secretion.
由于担心可能会加重肾毒性,环孢素治疗的移植患者经常避免使用H2受体拮抗剂。为了确定接受H2受体拮抗剂治疗的环孢素治疗移植患者中报告的血清肌酐水平升高是由于肾小球滤过率真正降低还是继发于肾小管对肌酐处理的改变,在11名接受环孢素治疗的肾移植受者中,在给予H2受体拮抗剂之前和之后分析了同时进行的菊粉和肌酐清除率。7名患者口服西咪替丁300 mg,每日4次,共1周,8名患者口服雷尼替丁150 mg,每日2次,共1周。在研究之前,所有患者的肾功能稳定,并维持使用泼尼松(平均剂量0.2±0.01 mg/kg/天)和环孢素(平均剂量5±0.6 mg/kg/天)。4名患者还接受硫唑嘌呤(2 mg/kg/天)。给予西咪替丁后,平均血清肌酐浓度从2.0±0.3 mg/dl显著增加(P<0.05)至2.4±0.3 mg/dl,平均肌酐清除率显著降低(P<0.05),而在此期间菊粉清除率保持不变。停药后所有患者的血清肌酐水平恢复到基线值。给予雷尼替丁对血清肌酐浓度、肌酐清除率或菊粉清除率没有一致的影响。两种药物均未改变环孢素谷浓度和血尿素氮。这些结果证实了先前的观察结果,即给予H2受体拮抗剂,尤其是西咪替丁后,血清肌酐升高,肌酐清除率降低。未能记录到菊粉清除率同时降低与以下假设一致,即H2受体拮抗剂不会加重环孢素肾毒性和降低肾小球滤过率,而是与肌酐竞争肾小管分泌。